Table 1 Characteristics of included trials for meta-analysis.
Author | Trial name | Type of study | Study design | Definition of hypomagnesemia | No. of Patients (Hypo-mg/ Normo-mg) |
|---|---|---|---|---|---|
Fujii et al.26 | N/A | Retrospective | Cetuximab or Panitumumab with mFOLFOX or FOLFIRI vs. mFOLFOX or FOLFIRI in the first-line treatment of mCRC | Grade 0 vs. grade 1–4 hypomagnesemia | 14/29 |
Vincenzi et al.23 | N/A | Retrospective | Cetuximab (400 mg/m2 loading dose, then 250 mg/m2 weekly) with irinotecan in the third-line treatment of mCRC | > 50% vs. < 50% reduction compared with basal value within 1 months from treatment | 95/48 |
Vickers et al.24 | NCIC CTG/ AGITG CO. 17 | RCT | Cetuximab (400 mg/m2 loading dose, then 250 mg/m2 weekly) with BSC vs. BSC alone in the third-line treatment of mCRC | Grade 0 vs. grade 1–4 hypomagnesemia | 53/163 |
Price et al.25 | ASPECCT | Conference presentation from phase III RCT | Panitumumab (6 mg/kg every 2 weeks) vs. Cetuximab (400 mg/m2 loading dose, then 250 mg/m2 weekly) in the third-line treatment of mCRC* | Grade 0 vs. grade 1–4 hypomagnesemia | Cetuximab group: 95/408 Panitumumab group: |
143/353 | |||||
Burkes et al.22 | PRIME | Conference presentation from phase III RCT | Panitumumab (6 mg/kg every 2 weeks) with FOLFOX4 vs. FOLFOX4 alone in the first-line treatment of mCRC | Grade 0 vs. grade 1–4 hypomagnesemia | 168/154 |
